Xoma Halts Development Of Acne Therapy XMP.629, Will Evaluate BPI Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Following disappointing Phase II results, Xoma will not conduct future trials with the bactericidal/permeability-increasing protein derivative XMP.629, its lead candidate. Earlier-stage BPI-derived products are under evaluation.
You may also be interested in...
Xoma’s New Business Strategy Emphasizes Proprietary Pipeline
Antibody developer’s near-term focus is on advancing its anti-inflammatory agent 052 and antimicrobial peptide 629 and partnering Neuprex.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.